Jaguar Health Launches Neonorm Dog but Liquidity Crisis Persists

What happened

Jaguar Health announced the commercial launch of Neonorm Dog, a plant-based non-prescription product for dogs designed to support normal stool consistency and GI fluid balance, with availability expected soon via Amazon and Chewy. This extends the existing Neonorm franchise beyond foals and calves, but the animal health segment has generated only $0.3 million in revenue over nine months, suggesting the product will have a marginal financial impact. The company remains in acute distress, with $3.5 million cash against $36.1 million current liabilities as of Q3 2025 and a locked-in royalty floor of approximately $27 million annually starting April 2026. Given that quarterly revenue is roughly $3.1 million and cash burn exceeds $6 million, the launch does not address the core funding cliff or the need for a major restructuring. Management likely views this as a low-cost brand extension, but it does not alter the fundamental solvency risk.

Implication

Neonorm Dog may add a modest revenue stream but is insufficient to offset Jaguar's fixed obligations or stem dilution. The strong sell thesis stays intact, and any positive price reaction from this launch should be treated as an opportunity to reduce exposure.

Thesis delta

The core bearish thesis remains unchanged: Jaguar faces structural insolvency risk due to overwhelming fixed royalty payments and inadequate revenue. The launch of Neonorm Dog is a minor operational event that does not address the $27 million annual royalty burden or the need for a major partnership or debt restructuring. Therefore, the investment thesis remains a strong sell.